Description

Waters Corporation’s Hidden Catalyst: $200 Million In Savings Meets Faster Growth!

Waters Corporation reported solid second quarter financial results, highlighted by revenue growth that exceeded guidance across its four operating divisions. Total revenue reached $1.645 billion, consisting of $828 million in organic revenue growing 9% on a constant currency basis and $817 million from the newly acquired Waters Biosciences and Diagnostic Solutions businesses, which grew 4% as reported. The company’s adjusted earnings per share rose 3% to $3.05, reaching the high end of guidance despite adverse foreign exchange impacts primarily from U.S. dollar strength. The Analytical Sciences segment showed strong performance with 9% constant currency growth, driven by instruments (+8%), chemistry (+10%), and services (+9%). Growth was supported by robust activity in pharmaceutical and academic/government end markets, alongside new product launches such as the Cyclic IMS P20 and Xevo MRT P10 mass spectrometers and several innovative columns in bioseparations.